EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Identification of potent pan-ephrin receptor kinase inhibitors using DNA-encoded chemistry technology

Chandrashekhar Madasu, Zian Liao iD, Sydney E Parks, Kiran L Sharma iD, Kurt M Bohren iD, Qiuji Ye iD, Feng Li iD, Murugesan Palaniappan iD, Zhi Tan, Fei Yuan, Chad J Creighton, Suni Tang und 5 weitere

Proceedings of the National Academy of Sciences · 07.05.2024 · 121 (19)

DOI: 10.1073/pnas.2322934121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 03.05.2024. Verfasst von Chandrashekhar Madasu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, NCI NIH HHS, HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EPH receptors (EPHs), the largest family of tyrosine kinases, phosphorylate downstream substrates upon binding of ephrin cell surface–associated ligands. In a large cohort of endometriotic lesions from individuals with endometriosis, we found that EPHA2 and EPHA4 expressions are increased in endometriotic lesions relative to normal eutopic endometrium. Because signaling through EPHs is associated with increased cell migration and invasion, we hypothesized that chemical inhibition of EPHA2/4 could have therapeutic value. We screened DNA-encoded chemical libraries (DECL) to rapidly identify EPHA2/4 kinase inhibitors. Hit compound, CDD-2693, exhibited picomolar/nanomolar kinase activity against EPHA2 (K i : 4.0 nM) and EPHA4 (K i : 0.81 nM). Kinome profiling revealed that CDD-2693 bound to most EPH family and SRC family kinases. Using NanoBRET target engagement assays, CDD-2693 had nanomolar activity versus EPHA2 (IC 50 : 461 nM) and EPHA4 (IC 50 : 40 nM) but was a micromolar inhibitor of SRC, YES, and FGR. Chemical optimization produced CDD-3167, having picomolar biochemical activity toward EPHA2 (K i : 0.13 nM) and EPHA4 (K i : 0.38 nM) with excellent cell-based potency EPHA2 (IC 50 : 8.0 nM) and EPHA4 (IC 50 : 2.3 nM). Moreover, CDD-3167 maintained superior off-target cellular selectivity. In 12Z endometriotic epithelial cells, CDD-2693 and CDD-3167 significantly decreased EFNA5 (ligand) induced phosphorylation of EPHA2/4, decreased 12Z cell viability, and decreased IL-1β-mediated expression of prostaglandin synthase 2 ( PTGS2 ). CDD-2693 and CDD-3167 decreased expansion of primary endometrial epithelial organoids from patients with endometriosis and decreased Ewing’s sarcoma viability. Thus, using DECL, we identified potent pan-EPH inhibitors that show specificity and activity in cellular models of endometriosis and cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsHumansFemaleEndometriosisDNAReceptors, Eph FamilyReceptor, EphA2Small Molecule LibrariesCell Movement

Stichwörter der Autor:innen

DNA-encoded chemistryendometriosisephrin receptor kinase inhibitors

Substanzen

Protein Kinase InhibitorsDNAReceptors, Eph FamilyReceptor, EphA2Small Molecule Libraries

Autor:innen und Institutionen

  • Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030.
  • Center for Drug Discovery, Baylor College of Medicine, Houston, TX 77030.
  • Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030.
  • Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX 77030.
  • Dan L. Duncan Comprehensive Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX 77030.
  • Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030.

ORCID-Profile: Zian Liao, Kiran L Sharma, Kurt M Bohren, Qiuji Ye, Feng Li, Murugesan Palaniappan, Martin M Matzuk

Förderung

  • NICHD NIH HHS
  • NCI NIH HHS
  • HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Burroughs Wellcome Fund
  • HHS | NIH | National Cancer Institute
  • Cancer Prevention and Research Institute of Texas

Zitieren

APA

Madasu, C., Liao, Z., Parks, S. E., Sharma, K. L., Bohren, K. M., Ye, Q., Li, F., Palaniappan, M., Tan, Z., Yuan, F., Creighton, C. J., Tang, S., Masand, R. P., Guan, X., Young, D. W., Monsivais, D., & Matzuk, M. M. (2024). Identification of potent pan-ephrin receptor kinase inhibitors using DNA-encoded chemistry technology. Proceedings of the National Academy of Sciences, 121(19). https://doi.org/10.1073/pnas.2322934121

Vancouver

Madasu C, Liao Z, Parks SE, Sharma KL, Bohren KM, Ye Q, et al. Identification of potent pan-ephrin receptor kinase inhibitors using DNA-encoded chemistry technology. Proceedings of the National Academy of Sciences. 2024;121(19). doi:10.1073/pnas.2322934121

BibTeX
@article{Madasu2024,
  author = {Madasu, Chandrashekhar and Liao, Zian and Parks, Sydney E and Sharma, Kiran L and Bohren, Kurt M and Ye, Qiuji and Li, Feng and Palaniappan, Murugesan and Tan, Zhi and Yuan, Fei and Creighton, Chad J and Tang, Suni and Masand, Ramya P and Guan, Xiaoming and Young, Damian W and Monsivais, Diana and Matzuk, Martin M},
  title = {Identification of potent pan-ephrin receptor kinase inhibitors using DNA-encoded chemistry technology},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {19},
  doi = {10.1073/pnas.2322934121}
}
Kostenlos starten →